Doubts raised about Provenge's efficacy; Breast cancer vaccine triggers an immune response;

> Activist Marie Huber has raised doubts about the efficacy of Provenge, the first therapeutic cancer vaccine, in prostate cancer. Article

> New hepatitis C antibodies could point to vaccine targets. Press release

> Generex Biotechnology subsidiary Antigen Express' AE37 breast cancer vaccine triggers an immune response, which could back up its ability to reduce recurrence. Press release

> Cancer stem cells could be used as an approach to cancer vaccination. Press release

> Astellas Pharma and Vical have finalized the design of a pivotal Phase III trial of TransVax, a therapeutic CMV vaccine for transplant recipients; the trial is planned for the second half of the year. Press release

> Whooping cough vaccine efficacy seems to wear off in pre-teens. Abstract | Article

> Merck ($MRK) has published efficacy and safety data for its shingles vaccine Zostavax in adults aged 50 to 59. Press release

> Bacillus Calmette-Guérin, a vaccine against tuberculosis, is a standard of care for some forms of bladder cancer; in Phase III trials, the Connaught strain of bacillus Calmette-Guérin is more effective than the Tice strain. Press release

> Inovio Pharmaceuticals ($INO) has received a U.S. Department of Defense SBIR grant to develop needle-free DNA vaccines against viruses with bioterrorism potential, including hanta, puumala, arenavirus and pandemic influenza. Press release

And Finally… Chile stops using mercury in vaccines. Press release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.